SINOCELLTECH GROUP LIMITED

北京神州细胞生物技术集团股份公司

Develops, manufactures and commercializes therapeutic antibodies, recombinant proteins and vaccines in China, with five commercialized products including rhFVIII Anjiayin, which ranked first in sales value among comparable products in China since 2023 per CIC, with about 35.5% market share in 2024.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Overlapping customers and suppliers
• Distribution model
• Single product, business line or region
• Pricing policy and price changes
• Outsourced production (OEM / contract manufacturing)
• Losses and path to profitability
• Decline in revenue or profit
• Working capital: receivables, prepayments and cash cycle
• Inventory level and ageing
• Non-recurring gains and losses